HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS Extends Choice Line For Diabetics With Foot Care, Oral Care Items

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb plans to extend its Choice DM line of products for people with diabetes to include foot care and oral care items, as well as nutritional bars and shakes, the firm announced at the National Association of Chain Drug Stores Marketplace in San Diego June 8-10

You may also be interested in...



Hi-Tech Diabetic Products To Play Key Role In Firm’s Growth Strategy

Hi-Tech Pharmacal plans to build up its Health Care Products Division through a two-pronged approach involving launching new products aimed at diabetics and expanding distribution channels

Excedrin Quick Tabs Will Be On OTC Shelves By Labor Day

Bristol-Myers Squibb will back the upcoming launch of Excedrin Quick Tabs with a six-month, $20 mil. advertising/marketing campaign, the firm said at the National Association of Chain Drug Stores Marketplace Conference in San Diego, Calif. June 15-18

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel